Morning Buzz: Aerie Pharmaceuticals (AERI), Cablevision Systems (CVC), Oracle

In a dramatic turnaround for Irvine, CA-based Aerie, which was forced to concede that its first Phase III had failed to hit the primary endpoint last April, the FDA provided written approval in June to change the primary endpoint for their second late-stage study-Rocket 2-“to include patients with baseline intraocular pressures ranging from above 20 mmHg (millimeters of mercury) to below 25 mmHg”.

In a phase 3 clinical trial, Rhopressa demonstrated non-inferiority to timolol. The 4.06M Company on September 16, 2015 declared that it has retained Roth Capital Partners as financial advisor to assist in a restructuring of the Company’s Series C Warrants.

Safety results are expected by the end of the year, or in early 2016. RBC Capital upped their price target on Aerie Pharmaceuticals from $31.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday. Aerie expects to file for USA regulatory approval for the drug by the middle of next year. Now that the economy has returned to pre-recession levels, the Fed is sitting in meetings discussing the potential rate hike.

Over the last six months, Aerie Pharmaceuticals NASDAQ:AERI has seen 0 unique insider buys, and 1 insider selling transaction.

Medivation Inc (NASDAQ:MDVN) reported the increase of 1.85% to close at $49.87 with the overall traded volume of 1.90 million shares. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Aerie also recently announced research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University as it further builds it pipeline for future growth. And Anido, who rarely misses a chance to tout the company’s prospects, says that an NDA is on track for filing in mid-2016 that will make the biotech a major contender in the ophthalmology market. Furthermore, treatment with Jardiance resulted in a lower risk of all-cause mortality (32 percent reduction) and hospitalization for heart failure (35 percent reduction). The company’s 50 day moving average price is $10.35 and its 200-day moving average price is $10.89. In a note shared with investors on 17 September, Aerie Pharmaceuticals (NASDAQ:AERI) stock had its “Buy” Rating kept by equity research analysts at Cantor Fitzgerald. In the long-term, the analyst believes that two-thirds of the company’s revenue is “exposed to secular growth trends in PC gaming (56% of revs); Auto (6%) and Accelerated Computing in the Cloud (6%)”. The Series C Warrants were issued as part of the Unit offering the Company completed on March 2, 2015.